Introduction to Healx and our technologies

AUTM Connect & Collaborate

Dr. Bruce Bloom, Chief Collaboration Officer

28 October, 2021



A few facts about Healx



Mission

Mission-driven company developing novel therapies for the 95% of rare diseases without effective treatments

Growth

High-growth AI tech company founded 2014 in Cambridge, UK. Closed Series A in 2018 and $56m Series B round in Q4 2019



Tech

Innovative AI and ML models derive novel disease-drug predictions from the world's most comprehensive rare disease knowledge graph

AI-powered, patient-inspired drug discovery

Patient insight is key

- Real world data contributed by patients
- Partnership model
- Rare Treatment Accelerator programme



Scalable AI / ML technology

- Outstanding performance metrics
- World class AI data scientists
- Most comprehensive rare disease knowledge graph

Strong drug discovery expertise

- Start with known drugs and nutraceuticals
- Rare disease know-how
- Expertise with a track record of drug discovery

healx

Building clinical pipelines – at scale



Co-development / in-licensing

Healx looking for **re-development assets** for **rare diseases** that are:

- From academic or industry partners
- Drug(s) approved for human use in one or more jurisdictions
- Deprioritized/shelved/discontinued assets that are safe for human use

Healx preferred deal arrangements:

- License preclinically proven assets ready for/close to clinical development
- Option/co-fund assets needing additional pre-clinical development

Keep in touch

Dr Bruce Bloom
Chief Collaboration Officer
bruce.bloom@healx.io

Dr Mark Youssef
Global Head of BD&L
mark.youssef@healx.io

Eugenia Wachters
VP Operations and
Commercial Portfolio Strategy
eugenia.wachters@healx.io

Dr Clara Tang
Business Manager – Alliance
Strategy Manager
clara.tang@healx.io

healx